Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

Related Keywords

Matthew Matasar ,Rutgers Cancer Institute ,Division Of Blood Disorders ,Rutgers Robert Wood Johnson Medical School ,Blood Disorders ,